{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-004269","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.520868+00:00","generated_at":"2026-06-07T01:59:46.793089+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Madrigal posts corporate presentation; full content not visible in filing text","bullets":["Madrigal posted a corporate presentation to its website for investor communications on January 8, 2024.","The presentation describes resmetirom as an investigational therapy not yet approved by FDA.","No specific new data or financial updates were extracted from the provided exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-004269","json":"https://secwatch.observer/filing/0001193125-24-004269.json","markdown":"https://secwatch.observer/filing/0001193125-24-004269.md","text":"https://secwatch.observer/filing/0001193125-24-004269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524004269/0001193125-24-004269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524004269/d669791d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:59:46.793089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}